0000950170-25-096268.txt : 20250716 0000950170-25-096268.hdr.sgml : 20250716 20250716161404 ACCESSION NUMBER: 0000950170-25-096268 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250715 FILED AS OF DATE: 20250716 DATE AS OF CHANGE: 20250716 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bredt David CENTRAL INDEX KEY: 0002022087 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-42121 FILM NUMBER: 251127606 MAIL ADDRESS: STREET 1: C/O RAPPORT THERAPEUTICS STREET 2: 1325 BOYLSTON ST., SUITE 401 CITY: BOSTON STATE: MA ZIP: 02215 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Rapport Therapeutics, Inc. CENTRAL INDEX KEY: 0002012593 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 880724208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 99 HIGH STREET STREET 2: SUITE 2100 CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 857-321-8020 MAIL ADDRESS: STREET 1: 99 HIGH STREET STREET 2: SUITE 2100 CITY: BOSTON STATE: MA ZIP: 02110 4 1 ownership.xml 4 X0508 4 2025-07-15 0002012593 Rapport Therapeutics, Inc. RAPP 0002022087 Bredt David RAPPORT THERAPEUTICS, INC. 99 HIGH STREET, SUITE 2100 BOSTON MA 02110 false true false false Chief Scientific Officer true Common Stock 2025-07-15 4 S false 8500 13.9955 D 435142 D These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.565 to $14.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. /s/ Troy Ignelzi, Attorney-in-Fact 2025-07-16